CME Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CME Group Inc is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company has strong financial performance, positive analyst sentiment, and upcoming product expansions that align with increasing demand. While technical indicators are neutral, the long-term growth potential and positive catalysts outweigh short-term fluctuations.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 39.562. Moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 295.499), suggesting limited downside risk in the short term.
Revenue and net income growth in Q4 2025 (26.71% and 35.23% YoY, respectively).
Expansion of the Equity Index Dividend suite and launch of Eris SOFR swap options, signaling innovation and market demand.
Positive analyst sentiment with multiple price target increases and 'Buy' ratings.
Neutral trading sentiment from hedge funds and insiders.
MACD and RSI indicators suggest no immediate bullish momentum.
Concerns about tough year-over-year comparisons for Q2 earnings.
In Q4 2025, CME Group achieved a 26.71% YoY revenue increase to $3.12 billion and a 35.23% YoY net income increase to $1.17 billion. EPS rose 35% YoY to $3.24, demonstrating strong profitability and growth.
Analysts are generally positive on CME Group, with multiple firms raising price targets (e.g., Piper Sandler to $329, Morgan Stanley to $362, TD Cowen to $340). The consensus leans toward 'Buy' or 'Overweight,' with some caution on Q2 comparisons.
